دورية أكاديمية

Comparison of the Subcutaneous and Intramuscular Estradiol Regimens as Part of Gender-Affirming Hormone Therapy.

التفاصيل البيبلوغرافية
العنوان: Comparison of the Subcutaneous and Intramuscular Estradiol Regimens as Part of Gender-Affirming Hormone Therapy.
المؤلفون: Herndon JS; Mayo Clinic Department of Medicine, Division of Endocrinology, Diabetes, Nutrition Rochester, Minnesota. Electronic address: herndon.justine@mayo.edu., Maheshwari AK; Midwest Endocrinology, Crystal Lake, Illinois., Nippoldt TB; Mayo Clinic Department of Medicine, Division of Endocrinology, Diabetes, Nutrition Rochester, Minnesota., Carlson SJ; Mayo Clinic Department of Medicine, Division of Endocrinology, Diabetes, Nutrition Rochester, Minnesota., Davidge-Pitts CJ; Mayo Clinic Department of Medicine, Division of Endocrinology, Diabetes, Nutrition Rochester, Minnesota., Chang AY; Mayo Clinic Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacksonville, Florida.
المصدر: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2023 May; Vol. 29 (5), pp. 356-361. Date of Electronic Publication: 2023 Mar 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9607439 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1530-891X (Print) Linking ISSN: 1530891X NLM ISO Abbreviation: Endocr Pract Subsets: MEDLINE
أسماء مطبوعة: Publication: 2021- : [New York] : Elsevier Inc.
Original Publication: Jacksonville, Fla. : The College and the Association,
مواضيع طبية MeSH: Estradiol* , Transgender Persons*, Humans ; Female ; Retrospective Studies ; Injections, Subcutaneous ; Androgen Antagonists ; Testosterone ; Injections, Intramuscular
مستخلص: Objective: Gender-affirming hormone therapy guidelines describe the estradiol (E2) doses for intramuscular (IM), but not subcutaneous (SC), routes. The objective was to compare the SC and IM E2 doses and hormone levels in transgender and gender diverse individuals.
Methods: This is a retrospective cohort study at a single-site tertiary care referral center. Patients were transgender and gender diverse individuals who received injectable E2 with at least 2 E2 measurements. The main outcomes were the dose and serum hormone levels between the SC and IM routes.
Results: There were no statistically significant differences in age, body mass index, or antiandrogen use between patients on SC (n = 74) and those on IM (n = 56). The weekly doses of SC E2, 3.75 mg (IQR, 3-4 mg), were statistically significantly lower than those of IM E2, 4 mg (IQR, 3-5.15 mg) (P =.005); however, the E2 levels achieved were not significantly different (P =.69), and the testosterone levels were in the cisgender female range and not significantly different between routes (P =.92). Subgroup analysis demonstrated significantly higher doses in the IM group when the E2 and testosterone levels were >100 pg/mL and <50 ng/dL, respectively, with the presence of the gonads or use of antiandrogens. Multiple regression analysis demonstrated that the dose was significantly associated with the E2 levels after adjusting for injection route, body mass index, antiandrogen use, and gonadectomy status.
Conclusion: Both the SC and IM E2 achieve therapeutic E2 levels without a significant difference in the dose (3.75 vs 4 mg). SC may achieve therapeutic levels at lower doses than IM .
Competing Interests: Disclosure The authors have no multiplicity of interest to disclose.
(Copyright © 2023 AACE. Published by Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: GAHT; estrogen; parenteral administration; transfeminine; transgender women
المشرفين على المادة: 4TI98Z838E (Estradiol)
0 (Androgen Antagonists)
3XMK78S47O (Testosterone)
تواريخ الأحداث: Date Created: 20230303 Date Completed: 20230509 Latest Revision: 20230509
رمز التحديث: 20231215
DOI: 10.1016/j.eprac.2023.02.006
PMID: 36868378
قاعدة البيانات: MEDLINE
الوصف
تدمد:1530-891X
DOI:10.1016/j.eprac.2023.02.006